Clinical Research Directory
Browse clinical research sites, groups, and studies.
Lp(a) Lowering Study of Pelacarsen (TQJ230) in Patients in the US With Elevated Lp(a) and Recent ACS (STEMI/NSTEMI) - Lp(a)FRONTIERS PEARL
Sponsor: Novartis Pharmaceuticals
Summary
CTQJ230A1US13 is a randomized, double-blind, placebo-controlled, multicenter phase IIIb study designed to evaluate the efficacy, safety, tolerability, and coronary plaque effects of early pelacarsen (TQJ230) initiation in participants with elevated Lp(a) and recent acute coronary syndrome (ACS).
Official title: A Randomized, Double-blind, Placebo-controlled, Multicenter Study Evaluating the Efficacy, Safety, Tolerability, and Coronary Plaque Effects of Early Pelacarsen (TQJ230) Initiation in Patients in the US With Elevated Lp(a) and Recent Acute Coronary Syndrome
Key Details
Gender
All
Age Range
18 Years - 79 Years
Study Type
INTERVENTIONAL
Enrollment
0
Start Date
2026-09-01
Completion Date
2029-01-22
Last Updated
2026-10-14
Healthy Volunteers
No
Conditions
Interventions
Pelacarsen
Pelacarsen 80 mg subcutaneously (s.c.) once a month (QM)
Placebo
Placebo subcutaneously (s.c.) once a month (QM)